Corporate Profile for InSite Vision, Inc., dated Jan. 22.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: Jan. 22, 1999
Company Name: InSite Vision, Inc.
Address: 965 Atlantic Ave.
Alameda, CA 94501
Main Telephone
Number: 510/865-8800
Internet Home
Page Address
(URL): www.insitevision.com
Chief Executive
Officer: S. Kumar Chandrasekaran, Ph.D.
Chief Financial
Officer: Michael D. Baer
Investor Relations
Contact: Sandi Heine
Business number: 510/865-8800
Trading Symbol/
Exchange: ISV/AMEX
Industry: Biopharmaceuticals
-0- Company description: InSite Vision, the industry leader in glaucoma glaucoma (glôkō`mə), ocular disorder characterized by pressure within the eyeball caused by an excessive amount of aqueous humor (the fluid substance filling the eyeball). genetics research, develops ophthalmic ophthalmic /oph·thal·mic/ (of-thal´mik) ocular (1). oph·thal·mic adj. Of or relating to the eye; ocular. Ophthalmic Pertaining to the eye. products for the diagnosis and treatment of ocular ocular /oc·u·lar/ (ok´u-lar) 1. of, pertaining to, or affecting the eye. 2. eyepiece. oc·u·lar adj. 1. Of or relating to the eye or the sense of sight. diseases such as glaucoma, macular degeneration macular degeneration, eye disorder causing loss of central vision. The affected area, the macula, lies at the back of the retina and is the part that produces the sharpest vision. and diabetic retinopathy diabetic retinopathy n. Retinal changes occurring in long-term diabetes and characterized by punctate hemorrhages, microaneurysms, and sharply defined waxy exudates. , which together afflict af·flict tr.v. af·flict·ed, af·flict·ing, af·flicts To inflict grievous physical or mental suffering on. [Middle English afflighten, from afflight, more than 15 million Americans. Today, the company has a pipeline of products that could significantly improve available treatments and change the drug delivery methods currently used in the $4 billion ophthalmology ophthalmology (ŏf'thălmŏl`əjē), branch of medicine specializing in the anatomy, function and diseases of the eye. Ophthalmologists specialize in the medical and surgical treatment of eye disorders, vision measurements for industry. Recognizing important gaps in today's inadequate ophthalmic treatments, Insite Vision focuses on three key applications in which the company is the leading pioneer. These are genetic tools for glaucoma diagnosis and prognosis, pharmaceutical products formulated around its proprietary sustained release Sustained-release (SR), extended-release (ER, XR, or XL), time-release or timed-release, controlled-release (CR), or continuous-release (CR or Contin DuraSite eye-drop based drug delivery system, and non-surgical delivery technology to administer drugs to the back of the eye. As a result, Insite Vision has emerged as an important bulwark against glaucoma -- the "silent thief of sight" -- and other eye diseases. From its inception, InSite Vision has employed creative approaches to product research and development. Early in a product's life cycle -- Phase I and most of Phase II development -- InSite's research team collaborates extensively with scientists at top research centers and leading universities. As development progresses to late Phase II, InSite carefully identifies and partners with a major pharmaceutical company, which completes the development and markets the product. This enables InSite Vision to focus on its inherent strength: early discovery and development of novel eye treatments. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion